"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
- Take with Food: Patients should be advised to take Sensipar with food or shortly after a meal. Tablets should be taken whole and should not be divided.
- Laboratory Monitoring: Patients should be informed of the importance of regular blood tests, in order to monitor the safety and efficacy of Sensipar therapy.
- Common Serious Adverse Reactions: Patients should be advised to report nausea, vomiting, and potential symptoms of hypocalcemia, including tingling/numbness of the skin, muscle pain, and muscle cramping.
- Seizures: Patients should be queried if they are taking medication to prevent seizures or have had seizures in the past and be advised to report any seizure episodes while on Sensipar therapy.
- Lactation Surveillance Program: Encourage patients who are nursing while on Sensipar treatment to enroll in Amgen's Lactation Surveillance Program. To enroll patients should call 1-800-77-AMGEN (1-800-772-6436).
Last reviewed on RxList: 12/11/2014
This monograph has been modified to include the generic and brand name in many instances.
Additional Sensipar Information
Sensipar - User Reviews
Sensipar User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.